The most frequently expressed EGFR variant in GBM, EGFRvIII (seen in 30% of patients [42]) comprises a constitutively active yet impaired tyrosine kinase receptor that is ligand-independent, activating anti-apoptotic and pro-invasive signaling pathways [43]. This evidence concerns the gene EGFR and glioblastoma.